Efficacy and Abuse Potential of Opioid Analgesics and the Treatment of Chronic Noncancer Pain

While the role of opioid analgesics has been established in the treatment of cancer pain, reservations persist about appropriate use in patients with chronic noncancer pain. Recent evidence from controlled clinical trials supports the effectiveness of opioids for treating noncancer pain of varying e...

Full description

Bibliographic Details
Main Authors: Andrew C Darke, John H Stewart
Format: Article
Language:English
Published: Hindawi Limited 1999-01-01
Series:Pain Research and Management
Online Access:http://dx.doi.org/10.1155/1999/352469
id doaj-d48205d44b484f63bb7742473a084eb1
record_format Article
spelling doaj-d48205d44b484f63bb7742473a084eb12020-11-24T23:17:10ZengHindawi LimitedPain Research and Management1203-67651999-01-014210410910.1155/1999/352469Efficacy and Abuse Potential of Opioid Analgesics and the Treatment of Chronic Noncancer PainAndrew C DarkeJohn H StewartWhile the role of opioid analgesics has been established in the treatment of cancer pain, reservations persist about appropriate use in patients with chronic noncancer pain. Recent evidence from controlled clinical trials supports the effectiveness of opioids for treating noncancer pain of varying etiologies. The safety of opioids in noncancer patients has been an area of controversy because of confusion between physical dependence, which develops in all patients receiving opioids chronically, and addiction, which is a behavioural diagnosis that is rarely made in patients appropriately treated with opioids for pain. Abuse by secondary recipients of opioids is well documented and arises as a result of diversion by primary recipients, double-doctoring, forgery and theft. The frequency of forgery and theft of different opioids appears to be largely related to the corresponding number of legitimate prescriptions. While it is legitimate medical practice to prescribe opioid analgesics to patients with chronic noncancer pain, there is clear evidence that prescribing is affected by concerns of regulatory sanctions. Recent guidelines, including most recently comprehensive guidelines issued by the Canadian Pain Society, should help to reduce inappropriate undertreatment because of such concerns.http://dx.doi.org/10.1155/1999/352469
collection DOAJ
language English
format Article
sources DOAJ
author Andrew C Darke
John H Stewart
spellingShingle Andrew C Darke
John H Stewart
Efficacy and Abuse Potential of Opioid Analgesics and the Treatment of Chronic Noncancer Pain
Pain Research and Management
author_facet Andrew C Darke
John H Stewart
author_sort Andrew C Darke
title Efficacy and Abuse Potential of Opioid Analgesics and the Treatment of Chronic Noncancer Pain
title_short Efficacy and Abuse Potential of Opioid Analgesics and the Treatment of Chronic Noncancer Pain
title_full Efficacy and Abuse Potential of Opioid Analgesics and the Treatment of Chronic Noncancer Pain
title_fullStr Efficacy and Abuse Potential of Opioid Analgesics and the Treatment of Chronic Noncancer Pain
title_full_unstemmed Efficacy and Abuse Potential of Opioid Analgesics and the Treatment of Chronic Noncancer Pain
title_sort efficacy and abuse potential of opioid analgesics and the treatment of chronic noncancer pain
publisher Hindawi Limited
series Pain Research and Management
issn 1203-6765
publishDate 1999-01-01
description While the role of opioid analgesics has been established in the treatment of cancer pain, reservations persist about appropriate use in patients with chronic noncancer pain. Recent evidence from controlled clinical trials supports the effectiveness of opioids for treating noncancer pain of varying etiologies. The safety of opioids in noncancer patients has been an area of controversy because of confusion between physical dependence, which develops in all patients receiving opioids chronically, and addiction, which is a behavioural diagnosis that is rarely made in patients appropriately treated with opioids for pain. Abuse by secondary recipients of opioids is well documented and arises as a result of diversion by primary recipients, double-doctoring, forgery and theft. The frequency of forgery and theft of different opioids appears to be largely related to the corresponding number of legitimate prescriptions. While it is legitimate medical practice to prescribe opioid analgesics to patients with chronic noncancer pain, there is clear evidence that prescribing is affected by concerns of regulatory sanctions. Recent guidelines, including most recently comprehensive guidelines issued by the Canadian Pain Society, should help to reduce inappropriate undertreatment because of such concerns.
url http://dx.doi.org/10.1155/1999/352469
work_keys_str_mv AT andrewcdarke efficacyandabusepotentialofopioidanalgesicsandthetreatmentofchronicnoncancerpain
AT johnhstewart efficacyandabusepotentialofopioidanalgesicsandthetreatmentofchronicnoncancerpain
_version_ 1725584554591256576